{"id":"recombinant-influenza-hemagglutinin","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"0c3cd915-babe-49c0-8aac-bf0247a17f3e","title":"FLUBLOK TRIVALENT NORTHERN HEMISPHERE (INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/DISTRICT OF COLUMBIA/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, AND INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN) INJECTION [SANOFI PASTEUR INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine antigen is produced through recombinant DNA technology and presents the hemagglutinin protein from influenza virus to the immune system. Hemagglutinin is the major surface antigen that the body recognizes and mounts an immune response against. By exposing the immune system to this purified recombinant protein, the vaccine induces both humoral (antibody) and cell-mediated immune responses that protect against subsequent influenza infection.","oneSentence":"Recombinant influenza hemagglutinin stimulates the immune system to produce antibodies and cellular immunity against influenza virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:26:51.868Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention"}]},"trialDetails":[{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT07240922","phase":"PHASE4","title":"The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-10-01","conditions":"Influenza","enrollment":600},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT04451954","phase":"PHASE1","title":"Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-07-02","conditions":"Influenza Immunisation, Healthy Volunteers","enrollment":210},{"nctId":"NCT05829356","phase":"PHASE1","title":"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-04-12","conditions":"Influenza Immunization","enrollment":159},{"nctId":"NCT04144179","phase":"PHASE1","title":"Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-06","conditions":"Influenza","enrollment":150},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT05409612","phase":"PHASE3","title":"Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-07","conditions":"Morbid Obesity, Severe Obesity","enrollment":206},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT06118151","phase":"PHASE1","title":"Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-04-11","conditions":"Influenza, Influenza Immunization","enrollment":388},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT05107375","phase":"PHASE3","title":"Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-09-03","conditions":"Coronavirus Disease 2019","enrollment":299},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT00539981","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09-15","conditions":"Influenza","enrollment":4648},{"nctId":"NCT03460743","phase":"PHASE3","title":"Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.","status":"COMPLETED","sponsor":"Laboratorios Liomont","startDate":"2018-03-22","conditions":"Influenza, Human","enrollment":1556},{"nctId":"NCT02335164","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2015-07","conditions":"Influenza","enrollment":270},{"nctId":"NCT03038776","phase":"PHASE1","title":"Recombinant H7 Hemagglutinin Influenza Vaccine Trial","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2017-01","conditions":"Influenza, Avian","enrollment":150},{"nctId":"NCT02285998","phase":"PHASE3","title":"Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":9003},{"nctId":"NCT02464163","phase":"PHASE1, PHASE2","title":"Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-07","conditions":"Influenza","enrollment":407},{"nctId":"NCT02600585","phase":"","title":"Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-11","conditions":"Human Influenza","enrollment":254648},{"nctId":"NCT01393951","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2011-05","conditions":"Healthy, Immunogenicity of ASP7374","enrollment":165},{"nctId":"NCT00489931","phase":"PHASE1","title":"Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-06-18","conditions":"Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A","enrollment":44},{"nctId":"NCT00408109","phase":"PHASE1","title":"Safety Study of Avian Flu Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-12-04","conditions":"Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A","enrollment":45},{"nctId":"NCT02290509","phase":"PHASE3","title":"Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1350},{"nctId":"NCT01959945","phase":"PHASE3","title":"Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2013-11","conditions":"Influenza","enrollment":219},{"nctId":"NCT01250795","phase":"PHASE1","title":"Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults","status":"COMPLETED","sponsor":"Fraunhofer, Center for Molecular Biotechnology","startDate":"2010-11","conditions":"Healthy","enrollment":100},{"nctId":"NCT01498718","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-12","conditions":"Influenza","enrollment":131},{"nctId":"NCT01612000","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2012-05","conditions":"Influenza","enrollment":341},{"nctId":"NCT00766285","phase":"PHASE2","title":"High Dose Influenza in Immunosuppressed Subjects","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza","enrollment":""},{"nctId":"NCT02434276","phase":"PHASE2","title":"Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2015-05","conditions":"Influenza","enrollment":450},{"nctId":"NCT02247362","phase":"PHASE1, PHASE2","title":"Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2014-11","conditions":"Influenza","enrollment":200},{"nctId":"NCT02015494","phase":"PHASE1","title":"Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention","status":"UNKNOWN","sponsor":"VaxInnate Corporation","startDate":"2014-03","conditions":"Influenza","enrollment":316},{"nctId":"NCT01825200","phase":"PHASE3","title":"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2013-03","conditions":"Influenza","enrollment":2640},{"nctId":"NCT00307177","phase":"PHASE2","title":"Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-08","conditions":"Influenza","enrollment":28},{"nctId":"NCT00966238","phase":"PHASE2","title":"Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age","status":"COMPLETED","sponsor":"VaxInnate Corporation","startDate":"2009-09","conditions":"Influenza","enrollment":120},{"nctId":"NCT00730457","phase":"PHASE1","title":"Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine","status":"COMPLETED","sponsor":"VaxInnate Corporation","startDate":"2008-07","conditions":"Influenza","enrollment":56},{"nctId":"NCT01147068","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2010-06","conditions":"Influenza","enrollment":392},{"nctId":"NCT00539864","phase":"PHASE3","title":"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2007-09","conditions":"Influenza","enrollment":602},{"nctId":"NCT00328107","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2004-11","conditions":"Influenza","enrollment":459},{"nctId":"NCT00395174","phase":"PHASE3","title":"Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2006-10","conditions":"Influenza","enrollment":870},{"nctId":"NCT00336453","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2006-10","conditions":"Influenza","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Panblok-H7"],"phase":"marketed","status":"active","brandName":"Recombinant influenza hemagglutinin","genericName":"Recombinant influenza hemagglutinin","companyName":"Vaxine Pty Ltd","companyId":"vaxine-pty-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Recombinant influenza hemagglutinin stimulates the immune system to produce antibodies and cellular immunity against influenza virus. Used for Influenza prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}